| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.YGYNO.2016.04.019 |
| P698 | PubMed publication ID | 27103175 |
| P50 | author | Keiichi Fujiwara | Q92525856 |
| P2093 | author name string | Antonio González-Martín | |
| Michael Birrer | |||
| Martin Gore | |||
| Amit Oza | |||
| Kei Muro | |||
| Susie Lau | |||
| Craig Davis | |||
| Brett Houk | |||
| Andres Poveda | |||
| Carolyn Muller | |||
| Mie Suzuki | |||
| Jennifer Vermette | |||
| Ashwin Gollerkeri | |||
| Josep María Del Campo | |||
| Kristen Pierce | |||
| P2860 | cites work | Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer. | Q51329014 |
| Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer | Q83223369 | ||
| Mutational analysis of gene families in human cancer | Q29038888 | ||
| Phosphoinositide kinases | Q29618047 | ||
| Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer | Q35072441 | ||
| First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer. | Q35868423 | ||
| Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation | Q37140110 | ||
| An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer | Q37187915 | ||
| Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes | Q37621799 | ||
| Emerging therapeutic targets in endometrial cancer | Q37827340 | ||
| New strategies in endometrial cancer: targeting the PI3K/mTOR pathway--the devil is in the details | Q38148744 | ||
| Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma | Q38388678 | ||
| PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity | Q39507948 | ||
| Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor | Q39591379 | ||
| Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome | Q44166101 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 62-69 | |
| P577 | publication date | 2016-04-18 | |
| P1433 | published in | Gynecologic Oncology | Q5625182 |
| P1476 | title | A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer | |
| P478 | volume | 142 |
| Q47130538 | A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer |
| Q48138303 | Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers. |
| Q91760324 | Distribution, Metabolism, and Excretion of Gedatolisib in Healthy Male Volunteers After a Single Intravenous Infusion |
| Q46764265 | Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification |
| Q33438286 | First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors |
| Q89599313 | Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma? |
| Q90444254 | Modulator of the PI3K/Akt oncogenic pathway affects mTOR complex 2 in human adenocarcinoma cells |
| Q92276603 | Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway |
| Q98164379 | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence |
| Q64254413 | Targeting PI3K in cancer: mechanisms and advances in clinical trials |
| Q99549077 | Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence |
| Q91814537 | Targeting mTOR and Metabolism in Cancer: Lessons and Innovations |
| Q91660586 | Targeting mTOR for cancer therapy |
| Q38982579 | mTORC1 and mTORC2 in cancer and the tumor microenvironment |
Search more.